STOCK TITAN

Yunqi Capital opposes Alcon deal for STAAR Surgical (NASDAQ: STAA) at $30.75

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
PX14A6G

Rhea-AI Filing Summary

Yunqi Capital, a 5.1% shareholder of STAAR Surgical, is urging investors to vote against the amended cash acquisition of STAAR by Alcon at $30.75 per share. In a detailed letter, Yunqi aligns with Glass Lewis’s continued recommendation against the deal and notes that ISS, while now supporting the merger, acknowledged it would not be unreasonable for shareholders to oppose it. Yunqi criticizes the robustness of STAAR’s go-shop process, pointing to a well-known potential buyer that appeared during the go-shop at a higher indicative price and was later publicly named by STAAR, which Yunqi believes discouraged that party.

Yunqi argues that STAAR’s standalone prospects remain attractive, citing proprietary ICL technology, global distribution, and strong demand trends, including an upcoming China launch of the EVO ICL V5 product line in January 2026 that it expects to carry about a 30–70% price premium over existing ICLs. Yunqi plans to vote its own shares against the merger and encourages other shareholders to do the same, while disclosing that its funds may continue to trade STAAR shares and derivatives over time.

Positive

  • None.

Negative

  • None.

Insights

Yunqi’s letter amplifies shareholder debate over STAAR’s sale to Alcon.

Yunqi Capital, holding 5.1% of STAAR Surgical, publicly opposes the proposed cash acquisition by Alcon at $30.75 per share. The firm aligns with Glass Lewis, which continues to recommend voting against the deal, and highlights that ISS, despite now supporting the transaction, stated it would not be unreasonable for shareholders to remain opposed. This positions Yunqi as a visible voice in a contested transaction, but it remains one stakeholder’s perspective rather than a determinative outcome.

The letter challenges the robustness of STAAR’s go-shop process, referencing a well-known potential acquirer that appeared during the go-shop with interest at a higher price and was later named in a press release. Yunqi interprets this sequence as evidence that more strategic or financial buyers could exist and suggests the public naming may have discouraged that party, supporting its call for terminating the current deal and pursuing a broader strategic review later. These are presented as Yunqi’s views and may resonate with shareholders who question process quality and pricing.

On fundamentals, Yunqi emphasizes STAAR’s proprietary ICL technology and demand trends, particularly in China. It cites STAAR management’s reference to “downward” Q4 2025 China sales trends as better than Yunqi’s expectations and points to the planned launch of the EVO ICL V5 line in China in January 2026, which Yunqi expects to be priced at roughly 30–70% above existing ICLs. If these assumptions prove accurate, higher average selling prices could support Yunqi’s view of solid standalone prospects, but actual impact will depend on adoption, pricing realization and future company disclosures.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

NOTICE OF EXEMPT SOLICITATION

Submitted Pursuant to Rule 14a-6(g)

 

(Amendment No. _)

 

 

 

1. Name of the Registrant:

 

STAAR SURGICAL CO

 

2. Name of Person Relying on Exemption:

 

Yunqi Capital Limited

 

3. Address of Person Relying on Exemption:

 

Unit 3703, 37/F, AIA Tower, 183 Electric Road, North Point, Hong Kong

 

4. Written Materials. The following written material is attached hereto:

 

Press release, dated December 17, 2025, attached hereto as Exhibit 1.

 

* * *

 

Written material is submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934, as amended. This is not a solicitation of authority to vote any proxy. Yunqi Capital Limited (together with its affiliates, “Yunqi Capital”) is not asking for your proxy card and will not accept proxy cards if sent. The cost of this filing is being borne entirely by Yunqi Capital.

 

PLEASE NOTE: Yunqi Capital is not asking for your proxy card and cannot accept your proxy card. Please DO NOT send us your proxy card.

 

(Written material follows on next page)

 

 

 

 

Exhibit 1

  

Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory

 

HONG KONG, December 17, 2025 – Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) regarding the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (SIX/NYSE: ALC).

 

The text of the letter is as follows:

 

December 17, 2025

 

Dear Fellow STAAR Shareholders:

 

Following our review of the updated reports of the proxy advisory services ISS and Glass Lewis, Yunqi Capital remains opposed to STAAR’s proposed merger with Alcon, even at the revised offer price of $30.75.

 

We agree with the continued, strong recommendation of Glass Lewis against the merger, as well as with the extensive rationale for Glass Lewis’s opposition set forth in its most recently updated report. While we disagree with ISS’s recent decision to change its recommendation in favor of the proposed transaction, we underscore that ISS also observed that “it would not necessarily be unreasonable for a shareholder to remain opposed to this transaction.”1

 

Recent events indicate shareholder value will be maximized if the Company terminates the current agreement and initiates a normal strategic alternatives review in the future.

 

When first announcing the conclusion of the go-shop period in a press release, STAAR did not inform shareholders about the appearance, during the go-shop period, of a well-known, credible potential buyer with the capital, industry expertise, buyout experience, and interest to acquire STAAR at a higher price. We are not taking issue with whether STAAR should have disclosed this in its first press release; we are simply highlighting that the third party emerged.

 

 

1Permission to use quotes was neither sought nor obtained.

 

 

 

 

STAAR then updated shareholders about the appearance of this new third party after questions were raised by other stockholders. When finally acknowledging the appearance of this third party in a second, follow-up press release, STAAR claimed that the potential buyer did not contact STAAR until the beginning of the third week of the go-shop period. STAAR related this claim as if it should be taken to undercut the credibility and meaningfulness of the third party’s outreach.

 

But STAAR’s confirmation of the third-party outreach illustrates the insufficiency of STAAR’s go-shop process.

 

STAAR had told shareholders in its first press release following the go-shop period, that it had solicited acquisition proposals from a “wide range of potentially interested third parties,” yet it missed a well-known and credible party, which also happens to have extensive experience and presence in Asia. STAAR then chose to name this third party in the same follow-up press release, in an unconventional manner. That appears to have chased away the third party, at least for the time being.

 

While the Company states that it engaged with 21 third parties, we believe there are far more than 21 potentially interested strategic and financial parties globally. We suspect that this third party and others like it will continue to be in the market in the future.

 

The Prospects for the Business Are Strong, in Spite of Leadership Changes that May Come

 

We were encouraged to see that ISS expressed well-founded skepticism about STAAR management’s pessimistic outlook for the future of the business. ISS stated that “shareholders continue to have a reason to question whether the board’s messaging about downside risk from an operational perspective is completely credible.”

 

We disagree with ISS on its primary basis for its change in recommendation. In reaching its conclusion, ISS focused on a concern that, if shareholders reject the transaction, “shareholders would need to be concerned about next steps for STAA,” since “shareholders cannot rely on the incumbent leadership team.”

 

Our view is that while leadership changes may follow a failed merger vote, the fundamentals of STAAR’s business remain firmly intact. In the near term, STAAR shareholders require continuity of operations and stewardship of the business while the Board recalibrates leadership at the senior level. The core drivers of STAAR’s value—its proprietary ICL technology, established global distribution infrastructure, and deep penetration in key growth markets—are unchanged. Moreover, the relevant economic data and market indicators underpinning the Company’s valuation point to solid and accelerating demand for ICL procedures, reinforcing our view that STAAR’s standalone prospects remain strong and continue to improve.

 

 

 

 

We also view positively STAAR management’s recent comments regarding, in their words, “downward” sales trends in China during the fourth quarter of 2025. Sales trends in the last quarter were already materially better than our expectations. Looking ahead, STAAR China is scheduled to launch the differentiated EVO ICL V5 product line in January 2026. In advance of this launch, we would expect distributors to reduce existing inventories in order to mitigate obsolescence risk and free up capital to support purchases of the new product, which would be priced at an approximately 30-70% premium to the existing line of ICLs, according to our on-the-ground research. This increase in blended average selling price provides an exciting sales driver for 2026 and is under-appreciated by the market.

 

This momentum in STAAR’s business should not be transferred to Alcon at substantially less than fair value simply because the Company may undertake leadership changes following this failed process. Alcon shareholders should not receive the benefit of this upside in place of STAAR’s long-term and loyal shareholders who understand this business and appreciate its value.

 

We will continue to vote our shares against the amended merger agreement, and we urge all shareholders to do the same and to continue to have confidence in the standalone prospects for STAAR.

 

Sincerely,

 

Christopher M. Wang

Founder and Chief Investment Officer

Yunqi Capital Limited

 

About Yunqi Capital

 

Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

 

Disclaimers

 

THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD OR OTHER VOTING INSTRUCTION FORM. YUNQI CAPITAL IS NOT ASKING FOR YOUR PROXY AND WILL NOT ACCEPT PROXY CARDS IF SENT. YUNQI CAPITAL IS NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

 

 

 

 

The information contained or referenced herein is for information purposes only in order to provide the views of Yunqi Capital and the matters which Yunqi Capital believes to be of concern to stockholders described herein. The information is not tailored to specific investment objectives, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Yunqi Capital, whose opinions may change at any time and which are based on analyses of Yunqi Capital and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Yunqi Capital’s rights, demands, grounds and/or remedies under any contract and/or law.

 

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “in our view”, “from our perspective”, “intends”, “estimates”, “plans”, “will be”, “would” and similar expressions. Although Yunqi Capital believes that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Yunqi Capital or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the U.S. Securities and Exchange Commission, including those listed under “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q and those related to the pending transaction involving the Company. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Yunqi Capital does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this material is based on data obtained from sources considered to be reliable. Any analyses provided to assist the recipient of this material in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and, unless required by law, are subject to revision without notice.

 

Funds and investment vehicles (collectively, the “Yunqi Funds”) managed or advised by Yunqi Capital currently beneficially own shares of the Company. The Yunqi Funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume the Yunqi Funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Yunqi Capital’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Yunqi Capital’s views of the pending transaction or the Company’s business, prospects, or valuations (including the market price of the Company shares), including, without limitation, other investment opportunities available to Yunqi Capital, concentration of positions in the portfolios managed by Yunqi Capital, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company’s share price on or following the date hereof, the Yunqi Funds may buy additional shares or sell all or a portion of their holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments). Yunqi Capital also reserves the right to change the opinions expressed herein and its intentions with respect to its investments in the Company, and to take any actions with respect to its investments in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

 

Contact

 

Chris Wang
cwang@yunqipath.com

 

 

 

 

About Yunqi Capital

 

Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

 

Disclaimers

 

THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD OR OTHER VOTING INSTRUCTION FORM. YUNQI CAPITAL IS NOT ASKING FOR YOUR PROXY AND WILL NOT ACCEPT PROXY CARDS IF SENT. YUNQI CAPITAL IS NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

 

The information contained or referenced herein is for information purposes only in order to provide the views of Yunqi Capital and the matters which Yunqi Capital believes to be of concern to stockholders described herein. The information is not tailored to specific investment objectives, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Yunqi Capital, whose opinions may change at any time and which are based on analyses of Yunqi Capital and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Yunqi Capital’s rights, demands, grounds and/or remedies under any contract and/or law. This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “in our view”, “from our perspective”, “intends”, “estimates”, “plans”, “will be”, “would” and similar expressions. Although Yunqi Capital believes that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Yunqi Capital or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the U.S. Securities and Exchange Commission, including those listed under “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q and those related to the pending transaction involving the Company. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Yunqi Capital does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this material is based on data obtained from sources considered to be reliable. Any analyses provided to assist the recipient of this material in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and, unless required by law, are subject to revision without notice.

 

 

 

 

Funds and investment vehicles (collectively, the “Yunqi Funds”) managed or advised by Yunqi Capital currently beneficially own shares of the Company. The Yunqi Funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume the Yunqi Funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Yunqi Capital’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Yunqi Capital’s views of the pending transaction or the Company’s business, prospects, or valuations (including the market price of the Company shares), including, without limitation, other investment opportunities available to Yunqi Capital, concentration of positions in the portfolios managed by Yunqi Capital, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company’s share price on or following the date hereof, the Yunqi Funds may buy additional shares or sell all or a portion of their holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments). Yunqi Capital also reserves the right to change the opinions expressed herein and its intentions with respect to its investments in the Company, and to take any actions with respect to its investments in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

 

Contact

 

Chris Wang
cwang@yunqipath.com

 

 

FAQ

What is Yunqi Capital asking STAAR Surgical (STAA) shareholders to do?

Yunqi Capital is asking STAAR Surgical shareholders to reject the amended merger agreement with Alcon at $30.75 per share and to support STAAR’s standalone path instead. Yunqi states it will vote its own shares against the transaction.

Why does Yunqi Capital oppose the Alcon acquisition of STAAR Surgical (STAA)?

Yunqi Capital believes the proposed $30.75 per share offer undervalues STAAR’s long-term potential. It argues that a credible potential buyer appeared during the go-shop period at a higher indicative price and that STAAR’s handling of the go-shop process was insufficient. Yunqi also highlights what it sees as strong business fundamentals and growth prospects for STAAR on a standalone basis.

How do ISS and Glass Lewis differ on the STAAR–Alcon merger recommendation?

According to Yunqi’s letter, Glass Lewis continues to strongly recommend that shareholders vote against the merger and provides detailed reasons for its opposition. ISS recently changed its recommendation to support the deal, but Yunqi notes ISS also stated that “it would not necessarily be unreasonable for a shareholder to remain opposed to this transaction.”

What business outlook does Yunqi Capital describe for STAAR Surgical (STAA)?

Yunqi Capital states that STAAR’s core value drivers—its proprietary ICL technology, global distribution, and penetration in key growth markets—remain intact. It references economic and market data that, in its view, indicate solid and improving demand for ICL procedures and argues that management’s pessimistic outlook has been questioned by ISS.

What does Yunqi Capital say about STAAR’s China business and EVO ICL V5?

Yunqi points to STAAR management’s comments on “downward” Q4 2025 China sales trends, noting these were better than its own expectations. It highlights the planned launch of the EVO ICL V5 product line in China in January 2026, which Yunqi expects to be priced at roughly 30–70% above existing ICLs, viewing this as an important potential sales driver.

How large is Yunqi Capital’s stake in STAAR Surgical (STAA) and what is its strategy?

The letter states that Yunqi Capital is a 5.1% shareholder of STAAR Surgical. Yunqi manages over US$250 million in assets and follows a fundamental long-short equity strategy focused on companies with a significant China connection. It discloses that its funds regularly trade STAAR’s securities and may buy or sell shares and derivatives over time.

Staar Surg

NASDAQ:STAA

View STAA Stock Overview

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

907.07M
49.44M
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
MONROVIA